Qamar, Arman
Bhatt, Deepak L.
Article History
First Online: 10 February 2015
Competing interests
: D.L.B. receives funding from Amarin, AstraZeneca, Bristol–Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi Aventis, and The Medicines Company; has performed unfunded research for FlowCo, PLx Pharma, and Takeda; is on the advisory board for Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences; the board of directors for the Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair of the American Heart Association Get With The Guidelines Steering Committee; Member of the Data Monitoring Committees of the Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Population Health Research Institute; has received honoraria from the American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Associate Editor; Section Editor, Pharmacology), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), WebMD (CME steering committees); and Clinical Cardiology (Deputy Editor). A.Q. declares no competing interests.